Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs

Donato Quaratino, Antonino Romano, Marina Di Fonso, Giuseppe Papa, Maria Rosaria Perrone, Francesco Purello D'Ambrosio, Alberto Venuti

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are frequent, particularly among patients with chronic urticaria or asthma. The need to identify an alternative drug that is safe and reliable is a common problem in clinical practice. Objective: To assess the tolerability of meloxicam, a new NSAID that selectively inhibits the inducible isoform of cyclooxygenase, in a group of NSAID-sensitive patients. Patients and Methods: We studied 177 patients who had suffered adverse reactions to one or more NSAIDs. Cutaneous reactions were reported by 83.1% of the subjects (urticaria in 55, angioedema in 52, urticaria/angioedema in 39, and maculopapular rash in 1), respiratory symptoms by 3.9%, both cutaneous and respiratory symptoms by 9%, Stevens-Johnson's syndrome by 2.3%, and anaphylactoid reactions by 1.7%. All subjects underwent a single-blind, placebo-controlled oral challenge with divided therapeutic doses of meloxicam (1.9 mg + 5.6 mg 1 hour later = cumulative dose 7.5 mg). Results: Positive reactions were observed in only two cases (1.1%), both manifested exclusively by cutaneous symptoms (urticaria/angioedema in one case and maculopapular rash/facial edema in the second). Conclusion: Meloxicam seems to be well tolerated by NSAID-sensitive subjects whose reactions are manifested by urticaria/angioedema. Additional study is needed for a more complete assessment of its tolerability in patients with aspirin-induced asthma and other severe manifestations of NSAID sensitivity.

Original languageEnglish
Pages (from-to)613-617
Number of pages5
JournalAnnals of Allergy, Asthma and Immunology
Volume84
Issue number6
Publication statusPublished - Jun 2000

Fingerprint

meloxicam
Anti-Inflammatory Agents
Urticaria
Angioedema
Pharmaceutical Preparations
Exanthema
Skin
Aspirin Induced Asthma
Stevens-Johnson Syndrome
Prostaglandin-Endoperoxide Synthases
Edema
Protein Isoforms

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Quaratino, D., Romano, A., Di Fonso, M., Papa, G., Perrone, M. R., D'Ambrosio, F. P., & Venuti, A. (2000). Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Annals of Allergy, Asthma and Immunology, 84(6), 613-617.

Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. / Quaratino, Donato; Romano, Antonino; Di Fonso, Marina; Papa, Giuseppe; Perrone, Maria Rosaria; D'Ambrosio, Francesco Purello; Venuti, Alberto.

In: Annals of Allergy, Asthma and Immunology, Vol. 84, No. 6, 06.2000, p. 613-617.

Research output: Contribution to journalArticle

Quaratino, D, Romano, A, Di Fonso, M, Papa, G, Perrone, MR, D'Ambrosio, FP & Venuti, A 2000, 'Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs', Annals of Allergy, Asthma and Immunology, vol. 84, no. 6, pp. 613-617.
Quaratino, Donato ; Romano, Antonino ; Di Fonso, Marina ; Papa, Giuseppe ; Perrone, Maria Rosaria ; D'Ambrosio, Francesco Purello ; Venuti, Alberto. / Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Annals of Allergy, Asthma and Immunology. 2000 ; Vol. 84, No. 6. pp. 613-617.
@article{7e67247b448d4bd49373481492aa64d8,
title = "Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs",
abstract = "Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are frequent, particularly among patients with chronic urticaria or asthma. The need to identify an alternative drug that is safe and reliable is a common problem in clinical practice. Objective: To assess the tolerability of meloxicam, a new NSAID that selectively inhibits the inducible isoform of cyclooxygenase, in a group of NSAID-sensitive patients. Patients and Methods: We studied 177 patients who had suffered adverse reactions to one or more NSAIDs. Cutaneous reactions were reported by 83.1{\%} of the subjects (urticaria in 55, angioedema in 52, urticaria/angioedema in 39, and maculopapular rash in 1), respiratory symptoms by 3.9{\%}, both cutaneous and respiratory symptoms by 9{\%}, Stevens-Johnson's syndrome by 2.3{\%}, and anaphylactoid reactions by 1.7{\%}. All subjects underwent a single-blind, placebo-controlled oral challenge with divided therapeutic doses of meloxicam (1.9 mg + 5.6 mg 1 hour later = cumulative dose 7.5 mg). Results: Positive reactions were observed in only two cases (1.1{\%}), both manifested exclusively by cutaneous symptoms (urticaria/angioedema in one case and maculopapular rash/facial edema in the second). Conclusion: Meloxicam seems to be well tolerated by NSAID-sensitive subjects whose reactions are manifested by urticaria/angioedema. Additional study is needed for a more complete assessment of its tolerability in patients with aspirin-induced asthma and other severe manifestations of NSAID sensitivity.",
author = "Donato Quaratino and Antonino Romano and {Di Fonso}, Marina and Giuseppe Papa and Perrone, {Maria Rosaria} and D'Ambrosio, {Francesco Purello} and Alberto Venuti",
year = "2000",
month = "6",
language = "English",
volume = "84",
pages = "613--617",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "6",

}

TY - JOUR

T1 - Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs

AU - Quaratino, Donato

AU - Romano, Antonino

AU - Di Fonso, Marina

AU - Papa, Giuseppe

AU - Perrone, Maria Rosaria

AU - D'Ambrosio, Francesco Purello

AU - Venuti, Alberto

PY - 2000/6

Y1 - 2000/6

N2 - Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are frequent, particularly among patients with chronic urticaria or asthma. The need to identify an alternative drug that is safe and reliable is a common problem in clinical practice. Objective: To assess the tolerability of meloxicam, a new NSAID that selectively inhibits the inducible isoform of cyclooxygenase, in a group of NSAID-sensitive patients. Patients and Methods: We studied 177 patients who had suffered adverse reactions to one or more NSAIDs. Cutaneous reactions were reported by 83.1% of the subjects (urticaria in 55, angioedema in 52, urticaria/angioedema in 39, and maculopapular rash in 1), respiratory symptoms by 3.9%, both cutaneous and respiratory symptoms by 9%, Stevens-Johnson's syndrome by 2.3%, and anaphylactoid reactions by 1.7%. All subjects underwent a single-blind, placebo-controlled oral challenge with divided therapeutic doses of meloxicam (1.9 mg + 5.6 mg 1 hour later = cumulative dose 7.5 mg). Results: Positive reactions were observed in only two cases (1.1%), both manifested exclusively by cutaneous symptoms (urticaria/angioedema in one case and maculopapular rash/facial edema in the second). Conclusion: Meloxicam seems to be well tolerated by NSAID-sensitive subjects whose reactions are manifested by urticaria/angioedema. Additional study is needed for a more complete assessment of its tolerability in patients with aspirin-induced asthma and other severe manifestations of NSAID sensitivity.

AB - Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are frequent, particularly among patients with chronic urticaria or asthma. The need to identify an alternative drug that is safe and reliable is a common problem in clinical practice. Objective: To assess the tolerability of meloxicam, a new NSAID that selectively inhibits the inducible isoform of cyclooxygenase, in a group of NSAID-sensitive patients. Patients and Methods: We studied 177 patients who had suffered adverse reactions to one or more NSAIDs. Cutaneous reactions were reported by 83.1% of the subjects (urticaria in 55, angioedema in 52, urticaria/angioedema in 39, and maculopapular rash in 1), respiratory symptoms by 3.9%, both cutaneous and respiratory symptoms by 9%, Stevens-Johnson's syndrome by 2.3%, and anaphylactoid reactions by 1.7%. All subjects underwent a single-blind, placebo-controlled oral challenge with divided therapeutic doses of meloxicam (1.9 mg + 5.6 mg 1 hour later = cumulative dose 7.5 mg). Results: Positive reactions were observed in only two cases (1.1%), both manifested exclusively by cutaneous symptoms (urticaria/angioedema in one case and maculopapular rash/facial edema in the second). Conclusion: Meloxicam seems to be well tolerated by NSAID-sensitive subjects whose reactions are manifested by urticaria/angioedema. Additional study is needed for a more complete assessment of its tolerability in patients with aspirin-induced asthma and other severe manifestations of NSAID sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=0033917977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033917977&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 613

EP - 617

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 6

ER -